NCT02885441

Treatment of Acute Pancreatitis With Ketorolac

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Ilam University of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients with acute pancreatitis will be randomly assigned in either study group to receive oral (injection) Ketorolac or the control group. In patients who cannot tolerate oral medications, ketorolac injection will be used.

Detailed description

Patients with acute pancreatitis will be randomly assigned in either study group or control group. * The study group will receive injection or oral Ketorolac. * The control group will receive standard medical treatment. Ketorolac is administrated three times daily by mouth or injection starting from the time of admission for the first three days of hospitalization (72 hours). Hs-CRP will be measured in admission in addition to standard laboratory tests.It will be done every day for up to 5 days, after the administration of study drug or till the time of discharge whichever occurs earlier. Patients will follow up for organ failure involvement and duration of hospitalization. The study will continue to gather clinical follow up information up to four months.

Conditions

• Acute Pancreatitis

Interventions

Type	Name	Description
DRUG	Ketorolac	Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.

Timeline

• Start date: 2016-09-01
• Primary completion: 2019-02-01
• Completion: 2019-02-01
• First posted: 2016-08-31
• Last updated: 2019-05-15

Locations

1 site across 1 country: Iran